Lebrikizumab is indicated for:
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Lebrikizumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Lebrikizumab is contraindicated in the following cases:
Ā© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
